The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.
NEWTON, Mass., March 25, 2024 Lumicell Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer detection during surgery, highlights presentations from clinical studies examining the use of investigational LUMISIGHT™ (pegulicianine) in combination with Lumicell™ Direct Visualization System (DVS) at the Society of Surgical Oncology Annual Meeting in Atlanta, Georgia, March 20-23, 2024.
Lumicell Announces FDA Advisory Committee's Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT in the Detection of Cancerous Tissue During Breast Conserving Surgery itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
Dr Park on the FDA Vote Supporting Lumisight Use for Breast Cancer Detection During Surgery onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.